首页 > 最新文献

Kidney Medicine最新文献

英文 中文
Proneurotensin/Neuromedin N and Risk of Incident CKD and Other Kidney Outcomes in Community-Living Individuals: The REGARDS Study 前神经紧张素/神经生长因子 N 与社区生活人群慢性肾脏病发病风险及其他肾脏结果:REGARDS研究
IF 3.9 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-04-24 DOI: 10.1016/j.xkme.2024.100831
Alexander L. Bullen , Alma Fregoso-Leyva , Ronit Katz , Dorothy Leann Long , Katharine L. Cheung , Suzanne E. Judd , Orlando M. Gutierrez , Joachim H. Ix , Mary Cushman , Dena E. Rifkin

Rationale & Objective

Plasma proneurotensin/neuromedin N (pro-NT/NMN) is a precursor of neurotensin, a tridecapeptide linked with type 2 diabetes mellitus and other comorbid conditions associated with kidney disease. Whether pro-NT/NMN is directly associated with incident chronic kidney disease (CKD), and whether that association differs by race, is uncertain. We evaluated whether pro-NT/NMN levels were associated with increased risk of kidney outcomes.

Study Design

Prospective cohort.

Setting & Participants

Participants in Biomarker Mediators of Racial Disparities in Risk Factors, a nested cohort from the REasons for Geographic And Racial Differences in Stroke study, with available stored serum and urine samples from baseline and second visits for biomarker measurement.

Exposure

Baseline log-transformed pro-NT/NMN.

Outcomes

Incident CKD, progressive estimated glomerular filtration rate (eGFR) decline, incident albuminuria, and incident kidney failure within median follow-up time of 9.4 years.

Analytical Approach

Logistic regression.

Results

Among 3,914 participants, the mean ± SD age was 64 ± 8 (SD) years, 48% were women, and 51% were Black. Median baseline eGFR was 90 (IQR, 77-102) mL/min/1.73 m2. Each SD higher of pro-NT/NMN was associated with 9% higher odds of progressive eGFR decline (OR, 1.09; 95% CI, 1.00-1.20). There was no association observed with incident CKD (OR, 1.10; 95% CI, 0.96-1.27), incident albuminuria (OR, 1.08; 95% CI, 0.96-1.22), or incident kidney failure (OR, 1.10; 95% CI, 0.83-1.46). There were no differences in results by race or sex.

Limitations

Single measurement of pro-NT/NMN and limited generalizability.

Conclusions

Higher pro-NT/NMN was associated with progressive eGFR decline but no other manifestations of kidney disease incidence.

Plain-Language Summary

Neurotensin is a peptide secreted by the small intestine in response to a meal. Higher levels of neurotensin and its stable precursor, proneurotensin/neuromedin N (pro-NT/NMN), have been associated with cardiovascular disease and type 2 diabetes mellitus, important risk factors for the development of kidney disease. Whether pro-NT/NMN is directly associated with kidney outcomes has been less studied and has been done so in largely homogenous cohorts of White participants. Using the REasons for Geographic And Racial Differences in Stroke study, we followed Black and White participants and evaluated the risk of developing kidney outcomes. We found that elevated levels of pro-NT/NMN were associated with kidney function decline. Pro-NT/NMN may help individuals who may benefit from closer monitoring of kidney function.

原理与amp; 目标血浆中的前神经紧张素/神经生长因子 N(pro-NT/NMN)是神经紧张素的前体,而神经紧张素是一种与 2 型糖尿病和其他与肾脏疾病相关的合并症有关的十三肽。原-NT/NMN是否与慢性肾脏病(CKD)直接相关,以及这种关系是否因种族而异,目前尚不确定。我们评估了pro-NT/NMN水平是否与肾脏预后风险的增加有关。研究设计前瞻性队列。研究地点& 参与者种族差异风险因素的生物标志物介导因素的参与者,该研究是中风的地域和种族差异原因研究的嵌套队列,基线和第二次就诊的血清和尿液样本可用于生物标志物测量。结果在中位随访时间为 9.4 年的时间内,发生 CKD、估计肾小球滤过率(eGFR)进行性下降、发生白蛋白尿和发生肾衰竭。结果在 3914 名参与者中,平均(± SD)年龄为 64 ± 8(SD)岁,48% 为女性,51% 为黑人。基线 eGFR 中位数为 90 (IQR, 77-102) mL/min/1.73 m2。pro-NT/NMN每升高一个标度,eGFR进行性下降的几率就会升高9%(OR,1.09;95% CI,1.00-1.20)。未观察到与慢性肾脏病(OR,1.10;95% CI,0.96-1.27)、白蛋白尿(OR,1.08;95% CI,0.96-1.22)或肾衰竭(OR,1.10;95% CI,0.83-1.46)的发生有关。结论较高的pro-NT/NMN与进行性eGFR下降有关,但与肾病发病率的其他表现无关。较高水平的神经紧张素及其稳定的前体--前神经紧张素/神经生长因子N(pro-NT/NMN)与心血管疾病和2型糖尿病有关,而这两种疾病是肾脏疾病发病的重要风险因素。至于pro-NT/NMN是否与肾脏疾病直接相关,目前研究较少,而且研究对象基本上是同质的白人参与者。我们利用 "中风的地域和种族差异原因 "研究,对黑人和白人参与者进行了跟踪调查,并评估了肾脏疾病的发病风险。我们发现,前 NT/NMN 水平升高与肾功能下降有关。前 NT/NMN 可帮助那些可能受益于肾功能密切监测的人。
{"title":"Proneurotensin/Neuromedin N and Risk of Incident CKD and Other Kidney Outcomes in Community-Living Individuals: The REGARDS Study","authors":"Alexander L. Bullen ,&nbsp;Alma Fregoso-Leyva ,&nbsp;Ronit Katz ,&nbsp;Dorothy Leann Long ,&nbsp;Katharine L. Cheung ,&nbsp;Suzanne E. Judd ,&nbsp;Orlando M. Gutierrez ,&nbsp;Joachim H. Ix ,&nbsp;Mary Cushman ,&nbsp;Dena E. Rifkin","doi":"10.1016/j.xkme.2024.100831","DOIUrl":"10.1016/j.xkme.2024.100831","url":null,"abstract":"<div><h3>Rationale &amp; Objective</h3><p>Plasma proneurotensin/neuromedin N (pro-NT/NMN) is a precursor of neurotensin, a tridecapeptide linked with type 2 diabetes mellitus and other comorbid conditions associated with kidney disease. Whether pro-NT/NMN is directly associated with incident chronic kidney disease (CKD), and whether that association differs by race, is uncertain. We evaluated whether pro-NT/NMN levels were associated with increased risk of kidney outcomes.</p></div><div><h3>Study Design</h3><p>Prospective cohort.</p></div><div><h3>Setting &amp; Participants</h3><p>Participants in Biomarker Mediators of Racial Disparities in Risk Factors, a nested cohort from the REasons for Geographic And Racial Differences in Stroke study, with available stored serum and urine samples from baseline and second visits for biomarker measurement.</p></div><div><h3>Exposure</h3><p>Baseline log-transformed pro-NT/NMN.</p></div><div><h3>Outcomes</h3><p>Incident CKD, progressive estimated glomerular filtration rate (eGFR) decline, incident albuminuria, and incident kidney failure within median follow-up time of 9.4 years.</p></div><div><h3>Analytical Approach</h3><p>Logistic regression.</p></div><div><h3>Results</h3><p>Among 3,914 participants, the mean<!--> <!-->±<!--> <!-->SD age was 64<!--> <!-->±<!--> <!-->8 (SD) years, 48% were women, and 51% were Black. Median baseline eGFR was 90 (IQR, 77-102) mL/min/1.73<!--> <!-->m<sup>2</sup>. Each SD higher of pro-NT/NMN was associated with 9% higher odds of progressive eGFR decline (OR, 1.09; 95% CI, 1.00-1.20). There was no association observed with incident CKD (OR, 1.10; 95% CI, 0.96-1.27), incident albuminuria (OR, 1.08; 95% CI, 0.96-1.22), or incident kidney failure (OR, 1.10; 95% CI, 0.83-1.46). There were no differences in results by race or sex.</p></div><div><h3>Limitations</h3><p>Single measurement of pro-NT/NMN and limited generalizability.</p></div><div><h3>Conclusions</h3><p>Higher pro-NT/NMN was associated with progressive eGFR decline but no other manifestations of kidney disease incidence.</p></div><div><h3>Plain-Language Summary</h3><p>Neurotensin is a peptide secreted by the small intestine in response to a meal. Higher levels of neurotensin and its stable precursor, proneurotensin/neuromedin N (pro-NT/NMN), have been associated with cardiovascular disease and type 2 diabetes mellitus, important risk factors for the development of kidney disease. Whether pro-NT/NMN is directly associated with kidney outcomes has been less studied and has been done so in largely homogenous cohorts of White participants. Using the REasons for Geographic And Racial Differences in Stroke study, we followed Black and White participants and evaluated the risk of developing kidney outcomes. We found that elevated levels of pro-NT/NMN were associated with kidney function decline. Pro-NT/NMN may help individuals who may benefit from closer monitoring of kidney function.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"6 6","pages":"Article 100831"},"PeriodicalIF":3.9,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000426/pdfft?md5=7ad0c198c6834e8031d4d4ea5f9aeb6e&pid=1-s2.0-S2590059524000426-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140775618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cystatin C Use for CKD Detection in the Veterans Health Administration System: A Qualitative Study of Barriers and Facilitators 退伍军人健康管理局系统使用胱抑素 C 检测 CKD:关于障碍和促进因素的定性研究
IF 3.9 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-04-22 DOI: 10.1016/j.xkme.2024.100830
Julio A. Lamprea-Montealegre , Abigail Shapiro , Natalie A.B. Bontrager , Dena E. Rifkin , Simerjot K. Jassal , Lucile Parker Gregg , Sankar D. Navaneethan , Krista Navarra , Michael G. Shlipak , Michelle M. Estrella , Virginia Wang
<div><h3>Rationale & Objective</h3><p>The measurement of cystatin C has been recommended to enhance chronic kidney disease (CKD) detection and risk stratification in clinical practice. This study gathered insights into the perceptions and experiences of clinical staff regarding the use of cystatin C in CKD detection within the Veterans Health Administration (VHA) system.</p></div><div><h3>Study Design</h3><p>A qualitative approach was employed to explore barriers and facilitators of clinical staff regarding the use of cystatin C in CKD detection within the VHA system. The Organizational Theory of Implementation Effectiveness informed the development of a semistructured interview guide.</p></div><div><h3>Setting & Participants</h3><p>Health care providers, nurses, and clinical pharmacists from the VHA systems in San Francisco, San Diego, and Houston were interviewed between October 2021 and May 2022.</p></div><div><h3>Exposures</h3><p>Participants' experiences with cystatin C testing.</p></div><div><h3>Outcomes</h3><p>Perceived barriers and facilitators to cystatin C testing.</p></div><div><h3>Analytical Approach</h3><p>Participant responses from individual interviews were analyzed by a multidisciplinary team using rapid qualitative analysis methods.</p></div><div><h3>Results</h3><p>Fourteen in-depth interviews were conducted across the 3 VHA systems. Ten of 11 providers worked in primary care. Five key barriers to using cystatin C for CKD detection were identified. These included lack of patient awareness of CKD testing, lack of provider awareness about cystatin C, knowledge barriers about cystatin C testing, unclear roles and ownership of CKD detection, and lack of clinic support to enhance CKD detection. Suggested interventions to overcome these barriers included educational and training programs, improved clinic workflows, and electronic health record aids to support CKD detection and use of cystatin C.</p></div><div><h3>Limitations</h3><p>The results may not be generalizable to other health care systems outside the VHA.</p></div><div><h3>Conclusions</h3><p>The findings indicate a need for targeted interventions such as educational and training programs, improved clinical workflows, and electronic health record aids to address barriers limiting the use of cystatin C in clinical practice for enhanced CKD detection.</p></div><div><h3>Plain-Language Summary</h3><p>This study assessed how clinical staff at the Veterans Health Administration (VHA) feel about using a test called cystatin C to help detect chronic kidney disease (CKD) earlier and more accurately. The research team spoke to healthcare providers, nurses, and clinical pharmacists in San Francisco, San Diego, and Houston between October 2021 and May 2022. We conducted 14 detailed interviews to understand the challenges and opportunities in using cystatin C for CKD detection. We found that participants often lacked awareness of CKD and the benefits of testing with cystatin C. There
研究原理与方法;目标胱抑素 C 的测定被推荐用于加强慢性肾脏病(CKD)的检测和临床实践中的风险分层。本研究收集了退伍军人健康管理局(VHA)系统内临床工作人员对使用胱抑素C检测慢性肾脏病的看法和经验。研究设计采用定性方法探讨了退伍军人健康管理局系统内临床工作人员对使用胱抑素C检测慢性肾脏病的障碍和促进因素。在 2021 年 10 月至 2022 年 5 月期间,研究人员对旧金山、圣地亚哥和休斯顿退伍军人管理局系统的医护人员、护士和临床药剂师进行了访谈。分析方法由一个多学科小组采用快速定性分析方法对个别访谈中参与者的回答进行分析。结果在 3 个退伍军人医疗保健系统中进行了 14 次深入访谈。11 位医疗服务提供者中有 10 位从事初级保健工作。确定了使用胱抑素 C 检测 CKD 的五个主要障碍。这些障碍包括患者对 CKD 检测缺乏认识、医疗服务提供者对胱抑素 C 缺乏认识、胱抑素 C 检测的知识障碍、CKD 检测的角色和所有权不明确以及缺乏诊所支持以加强 CKD 检测。为克服这些障碍而建议采取的干预措施包括教育和培训计划、改进诊所工作流程和电子健康记录辅助工具,以支持 CKD 检测和胱抑素 C 的使用。结论研究结果表明,有必要采取有针对性的干预措施,如教育和培训计划、改进临床工作流程和电子健康记录辅助工具,以解决临床实践中使用胱抑素 C 以提高 CKD 检测水平的障碍。2021 年 10 月至 2022 年 5 月期间,研究小组在旧金山、圣地亚哥和休斯顿采访了医疗服务提供者、护士和临床药剂师。我们进行了 14 次详细访谈,以了解使用胱抑素 C 检测 CKD 所面临的挑战和机遇。我们发现,参与者往往缺乏对 CKD 的认识,也不了解使用胱抑素 C 进行检测的益处。此外,他们对如何有效使用该检测方法的认识也存在差距,对由谁负责 CKD 检测也存在困惑,而且诊所内部需要更好地支持胱抑素 C 的使用。
{"title":"Cystatin C Use for CKD Detection in the Veterans Health Administration System: A Qualitative Study of Barriers and Facilitators","authors":"Julio A. Lamprea-Montealegre ,&nbsp;Abigail Shapiro ,&nbsp;Natalie A.B. Bontrager ,&nbsp;Dena E. Rifkin ,&nbsp;Simerjot K. Jassal ,&nbsp;Lucile Parker Gregg ,&nbsp;Sankar D. Navaneethan ,&nbsp;Krista Navarra ,&nbsp;Michael G. Shlipak ,&nbsp;Michelle M. Estrella ,&nbsp;Virginia Wang","doi":"10.1016/j.xkme.2024.100830","DOIUrl":"10.1016/j.xkme.2024.100830","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Rationale &amp; Objective&lt;/h3&gt;&lt;p&gt;The measurement of cystatin C has been recommended to enhance chronic kidney disease (CKD) detection and risk stratification in clinical practice. This study gathered insights into the perceptions and experiences of clinical staff regarding the use of cystatin C in CKD detection within the Veterans Health Administration (VHA) system.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Study Design&lt;/h3&gt;&lt;p&gt;A qualitative approach was employed to explore barriers and facilitators of clinical staff regarding the use of cystatin C in CKD detection within the VHA system. The Organizational Theory of Implementation Effectiveness informed the development of a semistructured interview guide.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Setting &amp; Participants&lt;/h3&gt;&lt;p&gt;Health care providers, nurses, and clinical pharmacists from the VHA systems in San Francisco, San Diego, and Houston were interviewed between October 2021 and May 2022.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Exposures&lt;/h3&gt;&lt;p&gt;Participants' experiences with cystatin C testing.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Outcomes&lt;/h3&gt;&lt;p&gt;Perceived barriers and facilitators to cystatin C testing.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Analytical Approach&lt;/h3&gt;&lt;p&gt;Participant responses from individual interviews were analyzed by a multidisciplinary team using rapid qualitative analysis methods.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;Fourteen in-depth interviews were conducted across the 3 VHA systems. Ten of 11 providers worked in primary care. Five key barriers to using cystatin C for CKD detection were identified. These included lack of patient awareness of CKD testing, lack of provider awareness about cystatin C, knowledge barriers about cystatin C testing, unclear roles and ownership of CKD detection, and lack of clinic support to enhance CKD detection. Suggested interventions to overcome these barriers included educational and training programs, improved clinic workflows, and electronic health record aids to support CKD detection and use of cystatin C.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Limitations&lt;/h3&gt;&lt;p&gt;The results may not be generalizable to other health care systems outside the VHA.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;p&gt;The findings indicate a need for targeted interventions such as educational and training programs, improved clinical workflows, and electronic health record aids to address barriers limiting the use of cystatin C in clinical practice for enhanced CKD detection.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Plain-Language Summary&lt;/h3&gt;&lt;p&gt;This study assessed how clinical staff at the Veterans Health Administration (VHA) feel about using a test called cystatin C to help detect chronic kidney disease (CKD) earlier and more accurately. The research team spoke to healthcare providers, nurses, and clinical pharmacists in San Francisco, San Diego, and Houston between October 2021 and May 2022. We conducted 14 detailed interviews to understand the challenges and opportunities in using cystatin C for CKD detection. We found that participants often lacked awareness of CKD and the benefits of testing with cystatin C. There","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"6 6","pages":"Article 100830"},"PeriodicalIF":3.9,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000414/pdfft?md5=f62bce0ebf263264571fdc25971176cc&pid=1-s2.0-S2590059524000414-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140766276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemodiafiltration versus Hemodialysis in End-Stage Kidney Disease: A Systematic Review and Meta-Analysis 终末期肾病中的血液滤过与血液透析:系统回顾和元分析
IF 3.9 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-04-18 DOI: 10.1016/j.xkme.2024.100829
Maria Gabriela Motta Guimarães , Fernanda Pinheiro Martin Tapioca , Naiara Rodrigues dos Santos , Fernanda Pitta do Carmo Tourinho Ferreira , Luiz Carlos Santana Passos , Paulo Novis Rocha

Rationale & Objective

The use of hemodiafiltration (HDF) as a kidney replacement therapy (KRT) in patients with end-stage kidney disease (ESKD) has sparked a debate regarding its advantages over conventional hemodialysis (HD). The present study aims to shed light on this controversy by comparing mortality rates and cause-specific deaths between ESKD patients receiving HDF and those undergoing HD.

Study Design

Systematic review and meta-analysis of randomized controlled trials (RCTs). The search was conducted using PubMed, EMBASE, and Cochrane Central on July 1, 2023.

Setting & Participants

Adult patients with ESKD on regular KRT.

Exposure

Studies with participants undergoing HDF.

Outcomes

Primary outcomes were all-cause mortality, cardiovascular (CV) mortality, deaths related to infections, and kidney transplant. We also evaluated the endpoints for deaths related to malignancy, myocardial infarction, stroke, arrhythmias, and sudden death.

Analytical Approach

We included RCTs evaluating HDF versus HD. Crossover trials and studies with overlapping populations were excluded. Two authors independently extracted the data following predefined search criteria and quality assessment. The risk of bias was assessed with Cochrane’s RoB2 tool.

Results

We included 5 RCTs with 4,143 patients, of which 2,078 (50.1%) underwent HDF, whereas 2,065 (49.8%) were receiving HD. Overall, HDF was associated with a lower risk of all-cause mortality (risk ratio [RR], 0.81; 95% confidence interval [CI], 0.73-0.91; P < 0.001; I2 = 7%) and a lower risk of CV-related deaths (RR, 0.75; 95% CI, 0.61-0.92; P = 0.007; I2 = 0%). The incidence of infection-related deaths was also significantly different between therapies (RR, 0.69; 95% CI, 0.50-0.95; P = 0.02; I2 = 26%).

Limitations

In individual studies, the HDF groups achieved varying levels of convection volume.

Conclusions

Compared with those undergoing HD, patients receiving HDF experienced a reduction in all-cause mortality, CV mortality, and infection-related mortality. These results provide compelling evidence supporting the use of HDF as a beneficial intervention in ESKD patients undergoing KRT.

Registration

Registered at PROSPERO: CRD42023438362.

基本原理与amp; Objective在终末期肾病(ESKD)患者中使用血液滤过(HDF)作为肾脏替代疗法(KRT)引发了有关其优于传统血液透析(HD)的争论。本研究旨在通过比较接受 HDF 和接受 HD 的 ESKD 患者的死亡率和特定病因死亡来揭示这一争议。结果主要结果为全因死亡率、心血管(CV)死亡率、感染相关死亡和肾移植。我们还评估了与恶性肿瘤、心肌梗死、中风、心律失常和猝死相关的死亡终点。分析方法我们纳入了评估 HDF 与 HD 的 RCT。排除了交叉试验和人群重叠的研究。两位作者按照预先确定的检索标准和质量评估独立提取数据。结果我们纳入了 5 项 RCT,共有 4,143 名患者,其中 2,078 人(50.1%)接受了 HDF 治疗,2,065 人(49.8%)接受了 HD 治疗。总体而言,HDF 与较低的全因死亡风险相关(风险比 [RR],0.81;95% 置信区间 [CI],0.73-0.91;P < 0.001;I2 = 7%),与较低的心血管相关死亡风险相关(RR,0.75;95% CI,0.61-0.92;P = 0.007;I2 = 0%)。结论与接受 HD 的患者相比,接受 HDF 的患者全因死亡率、CV 死亡率和感染相关死亡率均有所下降。这些结果提供了令人信服的证据,支持将 HDF 作为对接受 KRT 的 ESKD 患者有益的干预措施。注册在 PROSPERO:CRD42023438362。
{"title":"Hemodiafiltration versus Hemodialysis in End-Stage Kidney Disease: A Systematic Review and Meta-Analysis","authors":"Maria Gabriela Motta Guimarães ,&nbsp;Fernanda Pinheiro Martin Tapioca ,&nbsp;Naiara Rodrigues dos Santos ,&nbsp;Fernanda Pitta do Carmo Tourinho Ferreira ,&nbsp;Luiz Carlos Santana Passos ,&nbsp;Paulo Novis Rocha","doi":"10.1016/j.xkme.2024.100829","DOIUrl":"10.1016/j.xkme.2024.100829","url":null,"abstract":"<div><h3>Rationale &amp; Objective</h3><p>The use of hemodiafiltration (HDF) as a kidney replacement therapy (KRT) in patients with end-stage kidney disease (ESKD) has sparked a debate regarding its advantages over conventional hemodialysis (HD). The present study aims to shed light on this controversy by comparing mortality rates and cause-specific deaths between ESKD patients receiving HDF and those undergoing HD.</p></div><div><h3>Study Design</h3><p>Systematic review and meta-analysis of randomized controlled trials (RCTs). The search was conducted using PubMed, EMBASE, and Cochrane Central on July 1, 2023.</p></div><div><h3>Setting &amp; Participants</h3><p>Adult patients with ESKD on regular KRT.</p></div><div><h3>Exposure</h3><p>Studies with participants undergoing HDF.</p></div><div><h3>Outcomes</h3><p>Primary outcomes were all-cause mortality, cardiovascular (CV) mortality, deaths related to infections, and kidney transplant. We also evaluated the endpoints for deaths related to malignancy, myocardial infarction, stroke, arrhythmias, and sudden death.</p></div><div><h3>Analytical Approach</h3><p>We included RCTs evaluating HDF versus HD. Crossover trials and studies with overlapping populations were excluded. Two authors independently extracted the data following predefined search criteria and quality assessment. The risk of bias was assessed with Cochrane’s RoB2 tool.</p></div><div><h3>Results</h3><p>We included 5 RCTs with 4,143 patients, of which 2,078 (50.1%) underwent HDF, whereas 2,065 (49.8%) were receiving HD. Overall, HDF was associated with a lower risk of all-cause mortality (risk ratio [RR], 0.81; 95% confidence interval [CI], 0.73-0.91; <em>P</em> <!-->&lt;<!--> <!-->0.001; I<sup>2</sup> <!-->=<!--> <!-->7%) and a lower risk of CV-related deaths (RR, 0.75; 95% CI, 0.61-0.92; <em>P</em> <!-->=<!--> <!-->0.007; I<sup>2</sup> <!-->=<!--> <!-->0%). The incidence of infection-related deaths was also significantly different between therapies (RR, 0.69; 95% CI, 0.50-0.95; <em>P</em> <!-->=<!--> <!-->0.02; I<sup>2</sup> <!-->=<!--> <!-->26%).</p></div><div><h3>Limitations</h3><p>In individual studies, the HDF groups achieved varying levels of convection volume.</p></div><div><h3>Conclusions</h3><p>Compared with those undergoing HD, patients receiving HDF experienced a reduction in all-cause mortality, CV mortality, and infection-related mortality. These results provide compelling evidence supporting the use of HDF as a beneficial intervention in ESKD patients undergoing KRT.</p></div><div><h3>Registration</h3><p>Registered at PROSPERO: CRD42023438362.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"6 6","pages":"Article 100829"},"PeriodicalIF":3.9,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000402/pdfft?md5=e3c3711e7e84ef736a4090316fd2ad24&pid=1-s2.0-S2590059524000402-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140763663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complementary and Alternative Medicine Use and Glomerular Disease: A Contemporary Case Series 补充和替代药物的使用与肾小球疾病:当代病例系列
IF 3.9 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-04-17 DOI: 10.1016/j.xkme.2024.100827
Prem Kumar Devaraju , Jayalakshmi Seshadri , Chelvamalai Muthukumaran Balasubramanian , Anila Abraham Kurien , Guhan Senthilkumaran , Vaishanavi Devi Rajarathinam , Vijayakumar Stanlybai Jibia , Vinoj Murugesan , Tanuj Moses Lamech , Dineshkumar Thanigachalam , Sakthirajan Ramanathan , Sheik Sulthan Alavudeen , Shivakumar Dakshinamoorthy , Seenivasan Mookaiah , Natarajan Gopalakrishnan
<div><h3>Rationale & Objective</h3><p>Complementary and alternative medicine (CAM) intake is widely prevalent in many parts of India. Heavy metals are known ingredients in some of these formulations. We studied the spectrum of glomerular diseases in patients using CAM.</p></div><div><h3>Study Design</h3><p>Case series.</p></div><div><h3>Setting & Participants</h3><p>Patients with proteinuria or unexplained acute kidney injury, who underwent a kidney biopsy between May 2021 and September 2022, and who provided a history of recent CAM intake were included in the study. For patients enrolled prospectively, blood and urine samples were analyzed using mass spectrometry for the presence of mercury, lead, arsenic and cadmium. The CAM formulation, when available, was analyzed using inductively coupled plasma-optical emission spectroscopy.</p></div><div><h3>Results</h3><p>Twenty-eight patients were enrolled in the study, with a median duration of CAM intake of 4 months (interquartile range, 2-6 months). Heavy metal screening was performed in 17 patients, of whom 15 had elevated urine mercury levels, 10 had elevated blood mercury levels, and 1 had elevated blood and urine arsenic levels. Of the 6 CAM formulations that were analyzed, all had high levels of mercury. Kidney biopsy findings were membranous nephropathy (n<!--> <!-->=<!--> <!-->19), minimal change disease (n<!--> <!-->=<!--> <!-->8), and mesangial proliferative glomerulonephritis (n<!--> <!-->=<!--> <!-->1). Of the 19 patients with membranous nephropathy, 14 were associated with neural epidermal growth factor-like protein 1 (NELL-1). With conservative management alone, 17 patients achieved complete remission.</p></div><div><h3>Limitations</h3><p>Not all patients underwent blood and urine mercury testing, and only 6 patients provided the CAM samples for analysis. Furthermore, occupational and residential exposure to mercury could not be excluded.</p></div><div><h3>Conclusions</h3><p>The most common kidney pathology noted in our study was membranous nephropathy, which was predominantly associated with neural epidermal growth factor-like protein 1. A significant proportion of the patients recovered completely after withdrawal of the offending agent and initiation of renin-angiotensin system blockade.</p></div><div><h3>Plain Language Summary</h3><p>Complementary and alternative medicine (CAM) intake is widely prevalent in many parts of India, and heavy metals are known ingredients in some of these formulations. We describe the clinical spectrum of kidney disease, among patients who had recently ingested CAM. All patients underwent a kidney biopsy, and the most common finding was an entity called “NELL-1-associated membranous nephropathy,” which is known to be associated with heavy metal toxicity and CAM intake. Of 17 patients screened for such heavy metals, 15 had greater-than-permissible levels of mercury. Furthermore, 6 patients provided the CAM formulations that they had consumed for anal
理论依据& 目标在印度许多地区,补充和替代医学(CAM)的摄入非常普遍。重金属是其中一些配方的已知成分。我们研究了使用 CAM 的患者的肾小球疾病谱。研究设计病例系列。对于前瞻性入组的患者,血液和尿液样本采用质谱法分析汞、铅、砷和镉的含量。如果有 CAM 配方,则使用电感耦合等离子体-光发射光谱法对其进行分析。结果有 28 名患者被纳入研究,摄入 CAM 的时间中位数为 4 个月(四分位间范围为 2-6 个月)。对 17 名患者进行了重金属筛查,其中 15 人尿液汞含量升高,10 人血液汞含量升高,1 人血液和尿液砷含量升高。在分析的 6 种 CAM 配方中,所有配方的汞含量都很高。肾活检结果为膜性肾病(19 例)、微小病变(8 例)和间质增生性肾小球肾炎(1 例)。在 19 例膜性肾病患者中,14 例与神经表皮生长因子样蛋白 1(NELL-1)有关。局限性并非所有患者都接受了血液和尿液汞检测,只有 6 名患者提供了 CAM 样本用于分析。我们的研究发现,最常见的肾脏病变是膜性肾病,主要与神经表皮生长因子样蛋白 1 有关。在停用违规药物并开始肾素-血管紧张素系统阻断治疗后,相当一部分患者完全康复。我们描述了近期摄入 CAM 的患者肾脏疾病的临床表现。所有患者都接受了肾活检,最常见的发现是一种名为 "NELL-1相关膜性肾病 "的实体,众所周知,这种病与重金属中毒和摄入 CAM 有关。在接受重金属筛查的 17 名患者中,有 15 人的汞含量超过允许水平。此外,6 名患者提供了他们服用的 CAM 配方供分析:所有配方都含有高水平的汞。大多数此类患者在停用违规的 CAM 制剂后痊愈。
{"title":"Complementary and Alternative Medicine Use and Glomerular Disease: A Contemporary Case Series","authors":"Prem Kumar Devaraju ,&nbsp;Jayalakshmi Seshadri ,&nbsp;Chelvamalai Muthukumaran Balasubramanian ,&nbsp;Anila Abraham Kurien ,&nbsp;Guhan Senthilkumaran ,&nbsp;Vaishanavi Devi Rajarathinam ,&nbsp;Vijayakumar Stanlybai Jibia ,&nbsp;Vinoj Murugesan ,&nbsp;Tanuj Moses Lamech ,&nbsp;Dineshkumar Thanigachalam ,&nbsp;Sakthirajan Ramanathan ,&nbsp;Sheik Sulthan Alavudeen ,&nbsp;Shivakumar Dakshinamoorthy ,&nbsp;Seenivasan Mookaiah ,&nbsp;Natarajan Gopalakrishnan","doi":"10.1016/j.xkme.2024.100827","DOIUrl":"https://doi.org/10.1016/j.xkme.2024.100827","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Rationale &amp; Objective&lt;/h3&gt;&lt;p&gt;Complementary and alternative medicine (CAM) intake is widely prevalent in many parts of India. Heavy metals are known ingredients in some of these formulations. We studied the spectrum of glomerular diseases in patients using CAM.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Study Design&lt;/h3&gt;&lt;p&gt;Case series.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Setting &amp; Participants&lt;/h3&gt;&lt;p&gt;Patients with proteinuria or unexplained acute kidney injury, who underwent a kidney biopsy between May 2021 and September 2022, and who provided a history of recent CAM intake were included in the study. For patients enrolled prospectively, blood and urine samples were analyzed using mass spectrometry for the presence of mercury, lead, arsenic and cadmium. The CAM formulation, when available, was analyzed using inductively coupled plasma-optical emission spectroscopy.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;Twenty-eight patients were enrolled in the study, with a median duration of CAM intake of 4 months (interquartile range, 2-6 months). Heavy metal screening was performed in 17 patients, of whom 15 had elevated urine mercury levels, 10 had elevated blood mercury levels, and 1 had elevated blood and urine arsenic levels. Of the 6 CAM formulations that were analyzed, all had high levels of mercury. Kidney biopsy findings were membranous nephropathy (n&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;19), minimal change disease (n&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;8), and mesangial proliferative glomerulonephritis (n&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;1). Of the 19 patients with membranous nephropathy, 14 were associated with neural epidermal growth factor-like protein 1 (NELL-1). With conservative management alone, 17 patients achieved complete remission.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Limitations&lt;/h3&gt;&lt;p&gt;Not all patients underwent blood and urine mercury testing, and only 6 patients provided the CAM samples for analysis. Furthermore, occupational and residential exposure to mercury could not be excluded.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;p&gt;The most common kidney pathology noted in our study was membranous nephropathy, which was predominantly associated with neural epidermal growth factor-like protein 1. A significant proportion of the patients recovered completely after withdrawal of the offending agent and initiation of renin-angiotensin system blockade.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Plain Language Summary&lt;/h3&gt;&lt;p&gt;Complementary and alternative medicine (CAM) intake is widely prevalent in many parts of India, and heavy metals are known ingredients in some of these formulations. We describe the clinical spectrum of kidney disease, among patients who had recently ingested CAM. All patients underwent a kidney biopsy, and the most common finding was an entity called “NELL-1-associated membranous nephropathy,” which is known to be associated with heavy metal toxicity and CAM intake. Of 17 patients screened for such heavy metals, 15 had greater-than-permissible levels of mercury. Furthermore, 6 patients provided the CAM formulations that they had consumed for anal","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"6 6","pages":"Article 100827"},"PeriodicalIF":3.9,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000384/pdfft?md5=bae3d83b99a9605c9c8068d2e6b34e8b&pid=1-s2.0-S2590059524000384-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141068721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Review of Focal Segmental Glomerulosclerosis Classification With a Focus on Genetic Associations 病灶节段性肾小球硬化症分类综述,聚焦遗传相关性
IF 3.9 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-04-17 DOI: 10.1016/j.xkme.2024.100826
Marco Bonilla , Orhan Efe , Haresh Selvaskandan , Edgar V. Lerma , Nasim Wiegley

Focal segmental glomerulosclerosis (FSGS) defines a distinct histologic pattern observed in kidney tissue that is linked to several distinct underlying causes, all converging on the common factor of podocyte injury. It presents a considerable challenge in terms of classification because of its varied underlying causes and the limited correlation between histopathology and clinical outcomes. Critically, precise nomenclature is key to describe and delineate the pathogenesis, subsequently guiding the selection of suitable and precision therapies. A proposed pathomechanism-based approach has been suggested for FSGS classification. This approach differentiates among primary, secondary, genetic, and undetermined causes, aiming to provide clarity. Genetic FSGS from monogenic mutations can emerge during childhood or adulthood, and it is advisable to conduct genetic testing in cases in which there is a family history of chronic kidney disease, nephrotic syndrome, or resistance to treatment. Genome-wide association studies have identified several genetic risk variants, such as those in apolipoprotein L1 (APOL1), that play a role in the development of FSGS. Currently, no specific treatments have been approved to treat genetic FSGS; however, interventions targeting underlying cofactor deficiencies have shown potential in some cases. Furthermore, encouraging results have emerged from a phase 2 trial investigating inaxaplin, a novel small molecule APOL1 channel inhibitor, in APOL1-associated FSGS.

局灶节段性肾小球硬化症(FSGS)是肾脏组织中观察到的一种独特的组织学模式,它与几种不同的潜在病因有关,所有这些病因都与荚膜细胞损伤这一共同因素有关。由于其潜在病因多种多样,而且组织病理学与临床结果之间的相关性有限,因此在分类方面面临着相当大的挑战。至关重要的是,精确的命名是描述和划分发病机制的关键,从而指导选择合适的精准疗法。有人提出了一种基于病理机制的 FSGS 分类方法。这种方法区分了原发性、继发性、遗传性和未确定病因,旨在提供清晰的分类。单基因突变引起的遗传性 FSGS 可在儿童期或成年期出现,如果有慢性肾病、肾病综合征或耐药性家族史,建议进行基因检测。全基因组关联研究发现了几种遗传风险变异,如载脂蛋白 L1(APOL1)中的变异,这些变异在 FSGS 的发病中起着一定的作用。目前,治疗遗传性 FSGS 的特定疗法尚未获得批准;不过,针对潜在辅因子缺陷的干预措施已在某些病例中显示出潜力。此外,一项研究新型小分子 APOL1 通道抑制剂 inaxaplin 治疗 APOL1 相关性 FSGS 的 2 期试验也取得了令人鼓舞的结果。
{"title":"A Review of Focal Segmental Glomerulosclerosis Classification With a Focus on Genetic Associations","authors":"Marco Bonilla ,&nbsp;Orhan Efe ,&nbsp;Haresh Selvaskandan ,&nbsp;Edgar V. Lerma ,&nbsp;Nasim Wiegley","doi":"10.1016/j.xkme.2024.100826","DOIUrl":"10.1016/j.xkme.2024.100826","url":null,"abstract":"<div><p>Focal segmental glomerulosclerosis (FSGS) defines a distinct histologic pattern observed in kidney tissue that is linked to several distinct underlying causes, all converging on the common factor of podocyte injury. It presents a considerable challenge in terms of classification because of its varied underlying causes and the limited correlation between histopathology and clinical outcomes. Critically, precise nomenclature is key to describe and delineate the pathogenesis, subsequently guiding the selection of suitable and precision therapies. A proposed pathomechanism-based approach has been suggested for FSGS classification. This approach differentiates among primary, secondary, genetic, and undetermined causes, aiming to provide clarity. Genetic FSGS from monogenic mutations can emerge during childhood or adulthood, and it is advisable to conduct genetic testing in cases in which there is a family history of chronic kidney disease, nephrotic syndrome, or resistance to treatment. Genome-wide association studies have identified several genetic risk variants, such as those in apolipoprotein L1 (<em>APOL1</em>), that play a role in the development of FSGS. Currently, no specific treatments have been approved to treat genetic FSGS; however, interventions targeting underlying cofactor deficiencies have shown potential in some cases. Furthermore, encouraging results have emerged from a phase 2 trial investigating inaxaplin, a novel small molecule APOL1 channel inhibitor, in <em>APOL1</em>-associated FSGS.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"6 6","pages":"Article 100826"},"PeriodicalIF":3.9,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000372/pdfft?md5=94cd3108604d30cd53491d9615f30ee9&pid=1-s2.0-S2590059524000372-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140784394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
APOL1 Kidney Risk Variants and Long-Term Kidney Function in Healthy Middle-Aged Black Individuals: The Atherosclerosis Risk in Communities (ARIC) Study APOL1肾脏风险变异与健康中年黑人的长期肾功能:社区动脉粥样硬化风险(ARIC)研究
IF 3.9 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-04-17 DOI: 10.1016/j.xkme.2024.100828
Mona D. Doshi , Lihua Li , Abhijit S. Naik , Christie P. Thomas
<div><h3>Rationale & Objective</h3><p>The effect of apolipoprotein L1(<em>APOL1)</em> genotype on future risk of kidney disease among middle-aged individuals with good kidney function is not well established.</p></div><div><h3>Study Design</h3><p>Longitudinal cohort study.</p></div><div><h3>Setting & Participants</h3><p>In total, 5,886 healthy individuals (45-64 years old) enrolled in the Atherosclerosis Risk in Communities study with creatinine-based estimated glomerular filtration rate<!--> <!-->≥<!--> <!-->80<!--> <!-->mL/min who would be suitable kidney donors.</p></div><div><h3>Exposures</h3><p>Race and <em>APOL1</em> genotype.</p></div><div><h3>Outcomes</h3><p>Creatinine- and cystatin C-based estimated glomerular filtration rate (eGFRcr-cys) using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) 2021 equation, urinary albumin-creatinine ratio (UACR), proportion with chronic kidney disease (CKD) 3a or worse, end-stage kidney disease (ESKD), and death.</p></div><div><h3>Analytical Approach</h3><p>Participants grouped based on race and <em>APOL1</em> genotype. Compared eGFRcr-cys and UACR across groups. Multinomial logistic regression models were used compare odds of CKD. Kaplan–Meier survival curves were created to compare rates of ESKD and death at last follow-up.</p></div><div><h3>Results</h3><p>There were 5,075 Whites (86%), 701 Blacks carrying the low-risk <em>APOL1</em> genotype (12%), and 110 Blacks carrying the high-risk A<em>POL1</em> genotype (2%). The mean age at baseline was 53<!--> <!-->±<!--> <!-->6 years. At 10 years, White participants had lower eGFRcr-cys than low-risk and high-risk groups (89<!--> <!-->±<!--> <!-->16 vs 91<!--> <!-->±<!--> <!-->16 and 92<!--> <!-->±<!--> <!-->15<!--> <!-->mL/min/1.73<!--> <!-->m<sup>2</sup>, respectively; <em>P</em> <!--><<!--> <!-->0.001). At 25 years, White participants continued to have lower eGFRcr-cys than the low-risk group (70<!--> <!-->±<!--> <!-->18 vs 72<!--> <!-->±<!--> <!-->19<!--> <!-->mL/min/1.73<!--> <!-->m<sup>2</sup>; <em>P</em> <!--><<!--> <!-->0.001) but not compared with the high-risk <em>APOL1</em> genotype (67±23<!--> <!-->mL/min/1.73<!--> <!-->m<sup>2</sup>). There was no difference in UACR among groups at 10 and 25 years (<em>P</em> <!-->=<!--> <!-->0.87 and 0.91, respectively). The odds of developing CKD stage 3a or worse were not different between low-risk and high-risk <em>APOL1</em> group in both unadjusted and adjusted models (<em>P</em> <!-->=<!--> <!-->0.26 and <em>P</em> <!-->=<!--> <!-->0.39, respectively). At last follow-up,<!--> <!--><5% developed ESKD, and 45% of individuals either died or reached ESKD with no difference in outcomes between the groups.</p></div><div><h3>Limitations</h3><p>Low ascertainment because of death and long follow-up.</p></div><div><h3>Conclusions</h3><p>Among middle-aged individuals, <em>APOL1</em> genotype does not appear to be a major driver of future risk of kidney disease.</p></div><div><h3>Plain
研究设计纵向队列研究设定&参与者共有5886名健康人(45-64岁)参加了 "社区动脉粥样硬化风险"(Atherosclerosis Risk in Communities)研究,他们的肌酐估算肾小球滤过率≥80 mL/min,适合捐献肾脏。结果使用 CKD-EPI(慢性肾脏病流行病学协作组)2021 方程计算的基于肌酐和胱抑素 C 的估计肾小球滤过率 (eGFRcr-cys)、尿白蛋白-肌酐比值 (UACR)、慢性肾脏病 (CKD) 3a 或更严重的比例、终末期肾脏病 (ESKD) 和死亡。分析方法根据种族和 APOL1 基因型对参与者进行分组。比较各组 eGFRcr-cys 和 UACR。使用多项式逻辑回归模型比较 CKD 的几率。结果共有 5075 名白人(86%)、701 名携带低风险 APOL1 基因型的黑人(12%)和 110 名携带高风险 APOL1 基因型的黑人(2%)。基线时的平均年龄为 53 ± 6 岁。10 年时,白人参与者的 eGFRcr-cys 低于低风险组和高风险组(分别为 89 ± 16 vs 91 ± 16 和 92 ± 15 mL/min/1.73 m2; P < 0.001)。25 岁时,白人参与者的 eGFRcr-cys 仍低于低危组(70 ± 18 vs 72 ± 19 mL/min/1.73 m2;P <;0.001),但与高危 APOL1 基因型(67±23 mL/min/1.73 m2)相比则没有差异。在 10 年和 25 年时,各组间的 UACR 没有差异(P = 0.87 和 0.91)。在未调整模型和调整模型中,低风险和高风险 APOL1 组发生 CKD 3a 期或更严重的几率没有差异(分别为 P = 0.26 和 P = 0.39)。结论在中年人中,APOL1 基因型似乎不是未来肾病风险的主要驱动因素。通俗易懂的语言摘要携带两种载脂蛋白 L1(APOL1)基因变异型的肾病患者(称为高危基因型)的肾功能衰退速度要快于携带 0 个或 1 个风险变异型的患者。高风险基因型是否会对健康中年人的肾功能产生负面影响尚不清楚。我们评估了 APOL1 基因型对 "社区动脉粥样硬化风险 "研究参与者(平均年龄 53 岁)肾功能和血压基线正常的肾功能的影响。在 25 年的随访中,APOL1 高危基因型似乎并不是未来肾脏疾病风险的主要驱动因素。我们的研究结果对于为老年活体捐献者候选人以及 APOL1 相关肾病患者的家庭成员提供咨询具有重要意义。
{"title":"APOL1 Kidney Risk Variants and Long-Term Kidney Function in Healthy Middle-Aged Black Individuals: The Atherosclerosis Risk in Communities (ARIC) Study","authors":"Mona D. Doshi ,&nbsp;Lihua Li ,&nbsp;Abhijit S. Naik ,&nbsp;Christie P. Thomas","doi":"10.1016/j.xkme.2024.100828","DOIUrl":"10.1016/j.xkme.2024.100828","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Rationale &amp; Objective&lt;/h3&gt;&lt;p&gt;The effect of apolipoprotein L1(&lt;em&gt;APOL1)&lt;/em&gt; genotype on future risk of kidney disease among middle-aged individuals with good kidney function is not well established.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Study Design&lt;/h3&gt;&lt;p&gt;Longitudinal cohort study.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Setting &amp; Participants&lt;/h3&gt;&lt;p&gt;In total, 5,886 healthy individuals (45-64 years old) enrolled in the Atherosclerosis Risk in Communities study with creatinine-based estimated glomerular filtration rate&lt;!--&gt; &lt;!--&gt;≥&lt;!--&gt; &lt;!--&gt;80&lt;!--&gt; &lt;!--&gt;mL/min who would be suitable kidney donors.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Exposures&lt;/h3&gt;&lt;p&gt;Race and &lt;em&gt;APOL1&lt;/em&gt; genotype.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Outcomes&lt;/h3&gt;&lt;p&gt;Creatinine- and cystatin C-based estimated glomerular filtration rate (eGFRcr-cys) using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) 2021 equation, urinary albumin-creatinine ratio (UACR), proportion with chronic kidney disease (CKD) 3a or worse, end-stage kidney disease (ESKD), and death.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Analytical Approach&lt;/h3&gt;&lt;p&gt;Participants grouped based on race and &lt;em&gt;APOL1&lt;/em&gt; genotype. Compared eGFRcr-cys and UACR across groups. Multinomial logistic regression models were used compare odds of CKD. Kaplan–Meier survival curves were created to compare rates of ESKD and death at last follow-up.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;There were 5,075 Whites (86%), 701 Blacks carrying the low-risk &lt;em&gt;APOL1&lt;/em&gt; genotype (12%), and 110 Blacks carrying the high-risk A&lt;em&gt;POL1&lt;/em&gt; genotype (2%). The mean age at baseline was 53&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;6 years. At 10 years, White participants had lower eGFRcr-cys than low-risk and high-risk groups (89&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;16 vs 91&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;16 and 92&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;15&lt;!--&gt; &lt;!--&gt;mL/min/1.73&lt;!--&gt; &lt;!--&gt;m&lt;sup&gt;2&lt;/sup&gt;, respectively; &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0.001). At 25 years, White participants continued to have lower eGFRcr-cys than the low-risk group (70&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;18 vs 72&lt;!--&gt; &lt;!--&gt;±&lt;!--&gt; &lt;!--&gt;19&lt;!--&gt; &lt;!--&gt;mL/min/1.73&lt;!--&gt; &lt;!--&gt;m&lt;sup&gt;2&lt;/sup&gt;; &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0.001) but not compared with the high-risk &lt;em&gt;APOL1&lt;/em&gt; genotype (67±23&lt;!--&gt; &lt;!--&gt;mL/min/1.73&lt;!--&gt; &lt;!--&gt;m&lt;sup&gt;2&lt;/sup&gt;). There was no difference in UACR among groups at 10 and 25 years (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.87 and 0.91, respectively). The odds of developing CKD stage 3a or worse were not different between low-risk and high-risk &lt;em&gt;APOL1&lt;/em&gt; group in both unadjusted and adjusted models (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.26 and &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.39, respectively). At last follow-up,&lt;!--&gt; &lt;!--&gt;&lt;5% developed ESKD, and 45% of individuals either died or reached ESKD with no difference in outcomes between the groups.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Limitations&lt;/h3&gt;&lt;p&gt;Low ascertainment because of death and long follow-up.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;p&gt;Among middle-aged individuals, &lt;em&gt;APOL1&lt;/em&gt; genotype does not appear to be a major driver of future risk of kidney disease.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Plain","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"6 6","pages":"Article 100828"},"PeriodicalIF":3.9,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000396/pdfft?md5=03c5acaccdbaa3b7d1081f33c667e315&pid=1-s2.0-S2590059524000396-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140794290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urinary Oxalate Excretion During Pregnancy in Primary Hyperoxaluria Type 1: A Report of 4 Cases 原发性高草酸尿症 1 型患者妊娠期尿草酸盐排泄情况:4 例报告
IF 3.9 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-04-16 DOI: 10.1016/j.xkme.2024.100824
Jing Miao , Ramila A. Mehta , Andrea Kattah , Suzanne M. Norby , John C. Lieske , Dawn S. Milliner

Primary hyperoxaluria (PH) is a rare genetic disorder characterized by excessive oxalate production because of specific gene defects. PH1 is the most prevalent type, causing recurrent kidney stone disease and often leading to chronic kidney disease and kidney failure. Our previous study suggested that pregnancy did not adversely affect kidney function in female patients with PH. In this study, we identified 4 PH1 cases with urinary oxalate (UOx) measurements during pregnancy from the Rare Kidney Stone Consortium and Oxalosis and Hyperoxaluria Foundation PH registry to investigate UOx levels during pregnancy in patients with PH1. The PH Registry is approved by the Institutional Review Board of Mayo Clinic (Rochester, MN). All 4 showed a decrease in UOx during pregnancy when compared with before pregnancy and after delivery. These findings contrast with those of the general population, in which the UOx tends to increase during pregnancy because of a simultaneous physiological increase in the glomerular filtration rate. Elucidating the mechanism underlying reduced UOx during pregnancy in PH1 could suggest novel PH therapies. These findings could also affect the clinical management and have implications regarding the safety of withholding novel PH1-directed molecular therapies that currently have uncertain safety profiles during pregnancy. We highlight the need for additional data on urinary changes in patients with PH and other populations while pregnant to clarify changes in UOx throughout pregnancy.

原发性高草酸尿症(PH)是一种罕见的遗传性疾病,其特点是由于特定的基因缺陷而产生过多的草酸盐。PH1 是最常见的类型,可引起反复肾结石,通常会导致慢性肾病和肾衰竭。我们之前的研究表明,妊娠不会对 PH 女性患者的肾功能产生不利影响。在本研究中,我们从罕见肾结石联盟和草酸盐及高草酸盐尿症基金会 PH 登记处找到了 4 例 PH1 患者,并测量了她们在怀孕期间的尿草酸盐(UOx)水平,以调查 PH1 患者在怀孕期间的 UOx 水平。PH登记处获得了梅奥诊所(明尼苏达州罗切斯特市)机构审查委员会的批准。与怀孕前和分娩后相比,所有 4 人在怀孕期间的氧化亚氮水平都有所下降。这些研究结果与普通人群的研究结果形成了鲜明对比,普通人群在怀孕期间由于肾小球滤过率的生理性增加,尿氧化还原酶往往会增加。阐明PH1患者妊娠期尿氧化还原减少的机制可以为新型PH疗法提供建议。这些发现还可能影响临床管理,并对妊娠期暂停目前安全性尚不确定的新型 PH1 定向分子疗法的安全性产生影响。我们强调需要更多有关 PH 患者和其他人群在怀孕期间尿液变化的数据,以明确整个孕期的氧化亚氮变化。
{"title":"Urinary Oxalate Excretion During Pregnancy in Primary Hyperoxaluria Type 1: A Report of 4 Cases","authors":"Jing Miao ,&nbsp;Ramila A. Mehta ,&nbsp;Andrea Kattah ,&nbsp;Suzanne M. Norby ,&nbsp;John C. Lieske ,&nbsp;Dawn S. Milliner","doi":"10.1016/j.xkme.2024.100824","DOIUrl":"10.1016/j.xkme.2024.100824","url":null,"abstract":"<div><p>Primary hyperoxaluria (PH) is a rare genetic disorder characterized by excessive oxalate production because of specific gene defects. PH1 is the most prevalent type, causing recurrent kidney stone disease and often leading to chronic kidney disease and kidney failure. Our previous study suggested that pregnancy did not adversely affect kidney function in female patients with PH. In this study, we identified 4 PH1 cases with urinary oxalate (UOx) measurements during pregnancy from the Rare Kidney Stone Consortium and Oxalosis and Hyperoxaluria Foundation PH registry to investigate UOx levels during pregnancy in patients with PH1. The PH Registry is approved by the Institutional Review Board of Mayo Clinic (Rochester, MN). All 4 showed a decrease in UOx during pregnancy when compared with before pregnancy and after delivery. These findings contrast with those of the general population, in which the UOx tends to increase during pregnancy because of a simultaneous physiological increase in the glomerular filtration rate. Elucidating the mechanism underlying reduced UOx during pregnancy in PH1 could suggest novel PH therapies. These findings could also affect the clinical management and have implications regarding the safety of withholding novel PH1-directed molecular therapies that currently have uncertain safety profiles during pregnancy. We highlight the need for additional data on urinary changes in patients with PH and other populations while pregnant to clarify changes in UOx throughout pregnancy.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"6 6","pages":"Article 100824"},"PeriodicalIF":3.9,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000359/pdfft?md5=73a5ee830a46c3856615d37d3421b04a&pid=1-s2.0-S2590059524000359-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140796584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Kidney Injury and Subsequent Kidney Failure With Replacement Therapy Incidence in Older Adults With Advanced CKD: A Cohort Study of US Veterans 美国退伍军人队列研究:晚期慢性肾脏病老年人的 AKI 和后续肾衰竭替代疗法发生率
IF 3.9 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-04-16 DOI: 10.1016/j.xkme.2024.100825
Danira Medunjanin , Bethany J. Wolf , Roberto Pisoni , David J. Taber , John L. Pearce , Kelly J. Hunt
<div><h3>Rationale & Objective</h3><p>Advanced age is a major risk factor for chronic kidney disease (CKD) development, which has high heterogeneity in disease progression. Acute kidney injury (AKI) hospitalization rates are increasing, especially among older adults. Previous AKI epidemiologic analyses have focused on hospitalized populations, which may bias results toward sicker populations. This study examined the association between AKI and incident kidney failure with replacement therapy (KFRT) while evaluating age as an effect modifier of this relationship.</p></div><div><h3>Study Design</h3><p>Retrospective cohort study.</p></div><div><h3>Setting & Participants</h3><p>24,133 Veterans at least 65 years old with incident CKD stage 4 from 2011 to 2013.</p></div><div><h3>Exposures</h3><p>AKI, AKI severity, and age.</p></div><div><h3>Outcomes</h3><p>KFRT and death.</p></div><div><h3>Analytical Approach</h3><p>The Fine-Gray competing risk regression was used to model AKI and incident KFRT with death as a competing risk. A Cox regression was used to model AKI severity and death.</p></div><div><h3>Results</h3><p>Despite a nonsignificant age interaction between AKI and KFRT, a clinically relevant combined effect of AKI and age on incident KFRT was observed. Compared with our oldest age group without AKI, those aged 65-74 years with AKI had the highest risk of KFRT (subdistribution HR [sHR], 14.9; 95% CI, 12.7-17.4), whereas those at least 85 years old with AKI had the lowest (sHR, 1.71; 95% CI, 1.22-2.39). Once Veterans underwent KFRT, their risk of death increased by 44%. A 2-fold increased risk of KFRT was observed across all AKI severity stages. However, the risk of death increased with worsening AKI severity.</p></div><div><h3>Limitations</h3><p>Our study lacked generalizability, was restricted to ever use of medications, and used inpatient serum creatinine laboratory results to define AKI and AKI severity.</p></div><div><h3>Conclusions</h3><p>In this national cohort, advanced age was protective against incident KFRT but not death. This is likely explained by the high frequency of deaths observed in this population (51.1%). Nonetheless, AKI and younger age are substantial risk factors for incident KFRT.</p></div><div><h3>Plain Language Summary</h3><p>Older adults are at risk of acute kidney injury (AKI) and subsequent nonrecovery from AKI, resulting in long-term dialysis. Hospitalized patients have often been used in the past to study AKI. This could lead to biased conclusions when inferring from sicker populations. That is why we created a national cohort of 24,133 Veterans at least 65 years old with incident chronic kidney disease (CKD) stage 4 to examine the relationship between AKI and age and subsequent kidney failure with replacement therapy (KFRT). The data have showed that AKI and younger age are substantial risk factors for incident KFRT. As for older age, it appears to be protective against KFRT but not death. This is likely ex
理由与ampamp; 目标高龄是慢性肾脏病(CKD)发展的主要风险因素,而慢性肾脏病的发展具有高度异质性。急性肾损伤(AKI)住院率正在上升,尤其是在老年人中。以往的急性肾损伤流行病学分析主要针对住院人群,这可能会使分析结果偏向于病情较重的人群。本研究探讨了AKI与肾衰竭替代疗法(KFRT)之间的关系,同时评估了年龄对这一关系的调节作用。研究设计回顾性队列研究.研究地点及范围; 参与者24,133名退伍军人,年龄至少65岁,2011年至2013年期间发生CKD四期.暴露AKI、AKI严重程度和年龄.结果KFRT和死亡.分析方法Fine-Gray竞争风险回归用于模拟AKI和KFRT事件,死亡为竞争风险。结果尽管AKI和KFRT之间的年龄交互作用不显著,但观察到AKI和年龄对KFRT事件有临床相关的联合影响。与无 AKI 的最大年龄组相比,65-74 岁的 AKI 患者发生 KFRT 的风险最高(亚分布 HR [sHR],14.9;95% CI,12.7-17.4),而至少 85 岁的 AKI 患者发生 KFRT 的风险最低(sHR,1.71;95% CI,1.22-2.39)。一旦退伍军人接受了 KFRT,他们的死亡风险就会增加 44%。在所有 AKI 严重程度分期中,KFRT 的风险都增加了 2 倍。局限性我们的研究缺乏普遍性,仅限于曾经使用过的药物,并使用住院患者的血清肌酐化验结果来定义 AKI 和 AKI 严重程度。这可能是因为在该人群中观察到的死亡频率较高(51.1%)。白话摘要老年人面临急性肾损伤(AKI)的风险,随后可能无法从 AKI 中恢复,导致长期透析。过去常常使用住院患者来研究 AKI。这可能会导致从病情较重的人群中推断出有偏差的结论。因此,我们建立了一个由 24,133 名至少 65 岁、患有慢性肾脏病 (CKD) 4 期的退伍军人组成的全国队列,以研究 AKI 与年龄和随后的肾衰替代治疗 (KFRT) 之间的关系。数据显示,AKI 和较年轻的年龄是发生 KFRT 的主要风险因素。至于年龄较大,似乎对 KFRT 有保护作用,但对死亡没有保护作用。这可能是由于在我们的队列中观察到的高死亡频率造成的。
{"title":"Acute Kidney Injury and Subsequent Kidney Failure With Replacement Therapy Incidence in Older Adults With Advanced CKD: A Cohort Study of US Veterans","authors":"Danira Medunjanin ,&nbsp;Bethany J. Wolf ,&nbsp;Roberto Pisoni ,&nbsp;David J. Taber ,&nbsp;John L. Pearce ,&nbsp;Kelly J. Hunt","doi":"10.1016/j.xkme.2024.100825","DOIUrl":"10.1016/j.xkme.2024.100825","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Rationale &amp; Objective&lt;/h3&gt;&lt;p&gt;Advanced age is a major risk factor for chronic kidney disease (CKD) development, which has high heterogeneity in disease progression. Acute kidney injury (AKI) hospitalization rates are increasing, especially among older adults. Previous AKI epidemiologic analyses have focused on hospitalized populations, which may bias results toward sicker populations. This study examined the association between AKI and incident kidney failure with replacement therapy (KFRT) while evaluating age as an effect modifier of this relationship.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Study Design&lt;/h3&gt;&lt;p&gt;Retrospective cohort study.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Setting &amp; Participants&lt;/h3&gt;&lt;p&gt;24,133 Veterans at least 65 years old with incident CKD stage 4 from 2011 to 2013.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Exposures&lt;/h3&gt;&lt;p&gt;AKI, AKI severity, and age.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Outcomes&lt;/h3&gt;&lt;p&gt;KFRT and death.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Analytical Approach&lt;/h3&gt;&lt;p&gt;The Fine-Gray competing risk regression was used to model AKI and incident KFRT with death as a competing risk. A Cox regression was used to model AKI severity and death.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;Despite a nonsignificant age interaction between AKI and KFRT, a clinically relevant combined effect of AKI and age on incident KFRT was observed. Compared with our oldest age group without AKI, those aged 65-74 years with AKI had the highest risk of KFRT (subdistribution HR [sHR], 14.9; 95% CI, 12.7-17.4), whereas those at least 85 years old with AKI had the lowest (sHR, 1.71; 95% CI, 1.22-2.39). Once Veterans underwent KFRT, their risk of death increased by 44%. A 2-fold increased risk of KFRT was observed across all AKI severity stages. However, the risk of death increased with worsening AKI severity.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Limitations&lt;/h3&gt;&lt;p&gt;Our study lacked generalizability, was restricted to ever use of medications, and used inpatient serum creatinine laboratory results to define AKI and AKI severity.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;p&gt;In this national cohort, advanced age was protective against incident KFRT but not death. This is likely explained by the high frequency of deaths observed in this population (51.1%). Nonetheless, AKI and younger age are substantial risk factors for incident KFRT.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Plain Language Summary&lt;/h3&gt;&lt;p&gt;Older adults are at risk of acute kidney injury (AKI) and subsequent nonrecovery from AKI, resulting in long-term dialysis. Hospitalized patients have often been used in the past to study AKI. This could lead to biased conclusions when inferring from sicker populations. That is why we created a national cohort of 24,133 Veterans at least 65 years old with incident chronic kidney disease (CKD) stage 4 to examine the relationship between AKI and age and subsequent kidney failure with replacement therapy (KFRT). The data have showed that AKI and younger age are substantial risk factors for incident KFRT. As for older age, it appears to be protective against KFRT but not death. This is likely ex","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"6 6","pages":"Article 100825"},"PeriodicalIF":3.9,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000360/pdfft?md5=053368f03f34f71c9c2f30ed6622d81a&pid=1-s2.0-S2590059524000360-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140777873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases 肾移植后复发性 C3 肾小球病中的 B 因子抑制与 Iptacopan:两个病例的报告
IF 3.9 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-04-12 DOI: 10.1016/j.xkme.2024.100823
Víctor J. Escudero-Saiz , Ángela Gonzalez , Adriana García-Herrera , Ana B. Larque , Andrew S. Bomback , Laura Morantes , Marta Martínez-Chillarón , Júlia Ollé , Elena Guillén , Marc Xipell , Alicia Molina-Andújar , Diana Rodríguez , Elena Cuadrado , Judit Cacho , Carolt Arana , Núria Esforzado , Carla Bastida , Esteban Poch , Fritz Diekman , David Cucchiari , Miquel Blasco

C3 glomerulopathy is a rare disease caused by fluid phase dysregulation of the alternative complement pathway. Currently, treatment depends on clinical and histological severity and includes nephroprotection, unspecific immunosuppression, and terminal complement blockers (C5), without having an etiological treatment approved. C3 glomerulopathy has high recurrence rates after kidney transplantation with a high risk of graft loss. Fortunately, new molecules are being developed that specifically target the proximal alternative complement pathway, such as iptacopan, a factor B inhibitor that showed promising results in native kidneys and cases of transplant recurrence in a phase 2 clinical trial. We present 2 “real-world” cases of C3 glomerulopathy recurrence in kidney allografts treated with iptacopan, with initial excellent clinical response and safety profile, especially with early introduction. We also present follow-up biopsies that showed no C3 deposition during factor B inhibition. Our cases suggest that proximal blockade of the alternative complement pathway can be effective and safe in the treatment of C3 glomerulopathy recurrence in kidney transplantation, bringing other questions such as dual blockade (eg, in C3 and C5), the optimal patient profile to benefit from factor B inhibition or treatment duration and its potential use in other forms of membranoproliferative glomerulonephritis (eg, immune complex-mediated).

C3 肾小球病是一种罕见的疾病,由替代性补体途径的液相失调引起。目前,治疗方法取决于临床和组织学的严重程度,包括肾保护、非特异性免疫抑制和末端补体阻断剂(C5),但尚未批准病因治疗方法。C3 肾小球病在肾移植后的复发率很高,移植物丢失的风险也很高。幸运的是,目前正在开发专门针对近端替代补体途径的新分子,例如 B 因子抑制剂 iptacopan,在一项二期临床试验中,它在原生肾脏和移植复发病例中显示出良好的效果。我们介绍了两例接受伊帕考潘治疗的异体肾脏C3肾小球病复发的 "真实世界 "病例,这些病例最初的临床反应和安全性都非常好,尤其是在早期使用的情况下。我们还介绍了随访活检结果,结果显示因子 B 抑制期间没有 C3 沉积。我们的病例表明,近端阻断替代补体途径可有效、安全地治疗肾移植中的C3肾小球病复发,这也带来了其他问题,如双重阻断(如C3和C5)、从因子B抑制中获益的最佳患者情况或治疗持续时间,以及在其他形式的膜增生性肾小球肾炎(如免疫复合物介导的肾小球肾炎)中的潜在应用。
{"title":"Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases","authors":"Víctor J. Escudero-Saiz ,&nbsp;Ángela Gonzalez ,&nbsp;Adriana García-Herrera ,&nbsp;Ana B. Larque ,&nbsp;Andrew S. Bomback ,&nbsp;Laura Morantes ,&nbsp;Marta Martínez-Chillarón ,&nbsp;Júlia Ollé ,&nbsp;Elena Guillén ,&nbsp;Marc Xipell ,&nbsp;Alicia Molina-Andújar ,&nbsp;Diana Rodríguez ,&nbsp;Elena Cuadrado ,&nbsp;Judit Cacho ,&nbsp;Carolt Arana ,&nbsp;Núria Esforzado ,&nbsp;Carla Bastida ,&nbsp;Esteban Poch ,&nbsp;Fritz Diekman ,&nbsp;David Cucchiari ,&nbsp;Miquel Blasco","doi":"10.1016/j.xkme.2024.100823","DOIUrl":"10.1016/j.xkme.2024.100823","url":null,"abstract":"<div><p>C3 glomerulopathy is a rare disease caused by fluid phase dysregulation of the alternative complement pathway. Currently, treatment depends on clinical and histological severity and includes nephroprotection, unspecific immunosuppression, and terminal complement blockers (C5), without having an etiological treatment approved. C3 glomerulopathy has high recurrence rates after kidney transplantation with a high risk of graft loss. Fortunately, new molecules are being developed that specifically target the proximal alternative complement pathway, such as iptacopan, a factor B inhibitor that showed promising results in native kidneys and cases of transplant recurrence in a phase 2 clinical trial. We present 2 “real-world” cases of C3 glomerulopathy recurrence in kidney allografts treated with iptacopan, with initial excellent clinical response and safety profile, especially with early introduction. We also present follow-up biopsies that showed no C3 deposition during factor B inhibition. Our cases suggest that proximal blockade of the alternative complement pathway can be effective and safe in the treatment of C3 glomerulopathy recurrence in kidney transplantation, bringing other questions such as dual blockade (eg, in C3 and C5), the optimal patient profile to benefit from factor B inhibition or treatment duration and its potential use in other forms of membranoproliferative glomerulonephritis (eg, immune complex-mediated).</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"6 6","pages":"Article 100823"},"PeriodicalIF":3.9,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000347/pdfft?md5=b44683c9a22345d8860e8aacf690c347&pid=1-s2.0-S2590059524000347-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140784489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pretransplant Treatment to Avoid Recurrent Membranous Nephropathy in a Kidney Transplant Recipient: A Case Report 避免肾移植受者复发膜性肾病的移植前治疗:病例报告
IF 3.9 Q1 UROLOGY & NEPHROLOGY Pub Date : 2024-04-12 DOI: 10.1016/j.xkme.2024.100822
Erik L. Lum , Jonathan E. Zuckerman , Lama Abdelnour , Jennifer Terenzini , Gurbir Singh , Suphamai Bunnapradist

Kidney transplant candidates with high anti–M-type phospholipase A2 receptor antibody activity may be at increased risk for early postkidney transplant recurrence and allograft loss. Pretransplant treatment to induce serological remission may be warranted to improve allograft survival. In this case report, a patient seeking their third kidney transplant, who lost 2 prior living donor transplants from early recurrent membranous nephropathy, underwent pretransplant treatment for membranous nephropathy with serological remission and no evidence of recurrent disease.

抗 M 型磷脂酶 A2 受体抗体活性较高的肾移植候选者可能会增加肾移植后早期复发和异体移植损失的风险。可能需要进行移植前治疗以诱导血清学缓解,从而提高异体移植的存活率。在本病例报告中,一名寻求第三次肾移植的患者曾因早期复发性膜性肾病而失去两次活体移植机会,在接受移植前膜性肾病治疗后血清学缓解,且无复发迹象。
{"title":"Pretransplant Treatment to Avoid Recurrent Membranous Nephropathy in a Kidney Transplant Recipient: A Case Report","authors":"Erik L. Lum ,&nbsp;Jonathan E. Zuckerman ,&nbsp;Lama Abdelnour ,&nbsp;Jennifer Terenzini ,&nbsp;Gurbir Singh ,&nbsp;Suphamai Bunnapradist","doi":"10.1016/j.xkme.2024.100822","DOIUrl":"10.1016/j.xkme.2024.100822","url":null,"abstract":"<div><p>Kidney transplant candidates with high anti–M-type phospholipase A2 receptor antibody activity may be at increased risk for early postkidney transplant recurrence and allograft loss. Pretransplant treatment to induce serological remission may be warranted to improve allograft survival. In this case report, a patient seeking their third kidney transplant, who lost 2 prior living donor transplants from early recurrent membranous nephropathy, underwent pretransplant treatment for membranous nephropathy with serological remission and no evidence of recurrent disease.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"6 6","pages":"Article 100822"},"PeriodicalIF":3.9,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000335/pdfft?md5=d3c1b89f91dbce73ccd3cf483f24a0e1&pid=1-s2.0-S2590059524000335-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140781630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Kidney Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1